Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Key Points

• Cannon Advisors acquired 3,971 Thermo Fisher Scientific shares worth approximately $2.12 million in the second quarter, making TMO 1.3% of its portfolio. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03, beating estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The company provided fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $619.41, while insiders sold about $30.6 million of stock over the past three months. The company also declared a quarterly dividend of $0.47 per share, yielding approximately 0.3%.

Cannon Advisors Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,971 shares of the medical research company's stock, valued at approximately $2,121,000. Thermo Fisher Scientific comprises 1.3% of Cannon Advisors Inc.'s portfolio, making the stock its 17th biggest position.

A number of other hedge funds have also bought and sold shares of TMO. Salomon & Ludwin LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after purchasing an additional 17 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its holdings in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares during the period. Elyxium Wealth LLC increased its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after purchasing an additional 20 shares during the last quarter. Finally, Challenger Wealth Management raised its holdings in Thermo Fisher Scientific by 3.1% in the 2nd quarter. Challenger Wealth Management now owns 735 shares of the medical research company's stock valued at $298,000 after buying an additional 22 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 52,053 shares of company stock worth $30,643,589 in the last three months. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $588.17 on Friday. The business has a 50 day simple moving average of $529.37 and a 200-day simple moving average of $509.58. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market capitalization of $217.48 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Analysts Set New Price Targets

Several research analysts have weighed in on TMO shares. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price for the company. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. HSBC downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and dropped their target price for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source